Forteo denied as experimental or investigational by Cigna?

Cigna's specific coverage criteria for forteo are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Cigna Denied Forteo as Experimental

Teriparatide (Forteo) has FDA approval for treating osteoporosis in specific patient populations, so an "experimental or investigational" denial is almost always a classification or coding error — or it reflects Cigna applying its coverage policy to an off-label indication or a population subset it has not yet reviewed for your case. The denial letter should cite the specific provision triggering the experimental determination; that citation is the key to your appeal.

## Why This Denial Is Appealable

FDA approval establishes that a treatment is not experimental for its approved indications. If your prescriber is using teriparatide within an FDA-approved indication, the experimental label is factually wrong and should be corrected on appeal. If the use is off-label, the relevant standard under ERISA and most state laws is whether the use is supported by peer-reviewed medical literature and recognized clinical practice guidelines — not whether it appears in the policy's explicit list.

## Federal Appeal Framework

• Internal appeal: Submit within the window stated in your denial notice. For a non-urgent request, Cigna must decide within 30 days.
• External review (ACA §2719 / ERISA §503): After an internal denial, request IRO review within the ~4-month external review window. An independent clinical expert — not a Cigna employee — evaluates whether the treatment is truly experimental given current evidence. Expedited review is available when delay poses a serious health risk.

## Documentation to Gather

1. FDA approval documentation: A copy of the current FDA-approved prescribing label confirming the approved indication that matches your diagnosis. 2. Diagnosis confirmation: Physician notes, DXA results, fracture risk assessments establishing the clinical diagnosis. 3. Guideline support: A letter from your prescriber citing the applicable guideline organization (e.g., the Endocrine Society, AACE/ACE) that includes anabolic therapy in its recommendations for patients with your risk profile. 4. Prescriber medical-necessity letter: A detailed letter rebutting the experimental finding point-by-point, referencing the FDA label and guideline support.

## Criteria-Mapping Structure

Obtain the exact language from Cigna's coverage policy that triggered the experimental denial. For each criterion or exclusion listed, document the counter-evidence from the chart and from the FDA label. If a specific publication or guideline is referenced by Cigna's policy, confirm your prescriber addresses it directly. A point-by-point rebuttal submitted as a structured table dramatically increases reviewer efficiency and appeal success rates.